Association of systemic inflammatory markers with prognosis in erlotinib-treated EGFR-mutant non-small cell lung cancer

Yetişir A. E., PAYDAŞ S., Büyükşimşek M., Oğul A., Kolsuz İ., Kıdı M. M.

Journal of Cancer Research and Therapeutics, cilt.20, sa.1, ss.285-288, 2024 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 20 Sayı: 1
  • Basım Tarihi: 2024
  • Doi Numarası: 10.4103/jcrt.jcrt_1858_22
  • Dergi Adı: Journal of Cancer Research and Therapeutics
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, CINAHL, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.285-288
  • Anahtar Kelimeler: Derived neutrophil-lymphocyte ratio, erlotinib, lymphocyte-monocyte ratio, neutrophil-lymphocyte ratio, non-small cell lung cancer, platelet-lymphocyte ratio, prognosis
  • Çukurova Üniversitesi Adresli: Evet

Özet

Background: To evaluate the relationship of overall survival (OS) and progression-free survival (PFS) with the derived neutrophil-lymphocyte ratio (dNLR), neutrophil-lymphocyte ratio (NLR), lymphocyte-monocyte ratio (LMR), and platelet-lymphocyte ratio (PLR) in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). Methods: The study included 43 patients with EGFR-mutant metastatic NSCLC. The dNLR, NLR, LMR, and PLR values were calculated using the baseline complete blood counts before and after treatment with erlotinib. Results: The NLR value had the best diagnostic test performance with a sensitivity of 91.3%. dNLR, NLR, LMR, and PLR were found to be significant for the prediction of OS and PFS. While the delta dNLR and NLR values were significant for OS, only the delta NLR value was significant for PFS. Conclusions: The dNLR, NLR, LMR, and PLR values were found to be significant in the prediction of OS and PFS in erlotinib-treated metastatic NSCLC. Further clinical studies are needed to determine the ideal target-specific tyrosine kinase inhibitor in cases of metastatic NSCLC presenting with the EGFR-activating mutation.